Although trastuzumab deruxtecan has been proved resulting a survival benefit in patients with HER2-positive gastric cancer, no other new data have been obtained to date, and none of the new anti-HER2 treatment strategies improved survival significantly enough to justify registration6,20. The gene discussed is ERBB2; the disease is gastric cancer.